Skip to main content
. 2021 Mar 30;8(5):1064–1072. doi: 10.1002/acn3.51349

Table 1.

Change in retinal layer thickness during follow‐up for patients and controls.

Baseline

(P = 28, C = 29)

Year 1

(P = 27, C = 22)

Year 2

(P = 23, C = 26)

Change (95% CI) p‐value
pRNFL (total) a , µm patient 88.84 (2.10) 87.45 (2.10) 87.08 (2.11) −1.75 (−2.58 to −0.93) 0.001
control 92.19 (2.07) 92.63 (2.07) 92.32 (2.07) 0.13 (−0.98 to 1.25)
Superior patient 107.30 (2.93) 107.88 (2.93) 107.68 (2.94) 0.37 (−0.79 to 1.53) 0.990
control 116.52 (2.88) 117.13 (2.89) 117.00 (2.88) 0.48 (−1.36 to 1.80)
Nasal patient 69.98 (2.38) 66.00 (2.38) 65.12 (2.41) −.87 (−6.59 to −3.14) <0.001
control 66.26 (2.34) 67.25 (2.37) 65.80 (2.35) −0.46 (−2.80 to 1.86)
Inferior patient 114.64 (3.24) 113.08 (3.24) 112.66 (3.25) −1.98 (−3.09 to −0.88) 0.018
control 115.14 (3.18) 115.45 (3.19) 114.95 (3.19) −0.19 (−1.69 to 1.31)
Temporal patient 63.41 (2.48) 62.85 (2.48) 62.83 (2.49) −0.58 (−1.59 to 0.42) 0.165
control 70.85 (2.43) 70.66 (2.44) 71.56 (2.44) 0.72 (−0.52 to 2.08)
RNFL, µm patient 31.68 (0.69) 32.28 (0.69) 31.80 (0.69) 0.12 (−0.29 to 0.54) 0.140
control 34.21 (0.68) 33.97 (0.68) 34.09 (0.68) −0.12 (−0.70 to 0.45)
GCL, µm patient 37.21 (0.70) 37.14 (0.70) 36.85 (0.70) −0.36 (−0.60 to −0.11) 0.119
control 37.81 (0.68) 37.61 (0.69) 37.69 (0.68) −0.11 (−0.45 to 0.22)
EDSS 3.5 (0‐7.0) 3.5 (0‐7.5) 4.0 (0‐7.5) 0.44 (0.09 to 0.78) 0.014
SSPROM 85.25 (65‐100) 83.00 (59‐100) 81.50 (45.5‐100) −2.80 (−5.11 to −0.50) 0.018
Timed up‐and‐go, s 6.66 (2.57‐13.54) 7.39 (2.97‐15.25) 8.81 (2.77‐14.49) 0.60 (−11 to 1.31) 0.107

Retinal layer thickness and changes during follow‐up are the estimated values from the linear mixed‐effects models and summarized as means (standard errors). pRNFL (total) and GCL thickness are also presented in Figure 3 (green line for total patient group, blue lines for controls). P‐values represent the significance level of the interaction term “group * time” and signify whether the change in retinal layer thickness over time of patients differs from controls. For patients, change on clinical parameters is also reported. Values are summarized as median (range), change is reported as mean paired change between baseline and year 2 with corresponding p‐value (Wilcoxon signed rank test).

EDSS, expanded disability status scale; GCL, ganglion cell layer; pRNFL, peripapillary retinal nerve fiber layer; RNFL, retinal nerve fiber layer; SSPROM, severity scoring system for progressive myelopathy.

a

Mean thickness of the total peripapillary ring followed by each of the four quadrants.